{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Automatic Remifentanil Administration in Burn Surgery: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "52 adult patients were randomised into two groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included ASA I\u2013III patients scheduled for burn excision and skin grafts. Conducted at the Burn Center of the University Hospital of Lille, France"
      },
      "Intervention": {
        "score": 2,
        "evidence": "automatic remifentanil infusion using the ANI-REMI-LOOP software or manual infusion (standard practice)"
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed the clinical efficacy and safety of an expert system for automatic remifentanil administration during propofol anesthesia in burn surgery"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the cumulative remifentanil dose during anesthesia"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was performed using permutated blocks of four"
      },
      "Blinding": {
        "score": 1,
        "evidence": "patients were blinded to group allocation"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "52 adult patients were randomised into two groups: automatic remifentanil infusion using the ANI-REMI-LOOP software or manual infusion (standard practice). Conducted at the Burn Center of the University Hospital of Lille, France, from June 2018 to June 2022"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis was conducted on a per-protocol basis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The automatic group received a significantly lower cumulative remifentanil dose (0.125 \u00b5g.kg\u207b\u00b9.min\u207b\u00b9 [0.106 to 0.149]) compared to the manual group (0.152 \u00b5g.kg\u207b\u00b9.min\u207b\u00b9 [0.137 to 0.237], p = 0.004)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events related to the intervention were reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov NCT03556696"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}